Plasma cold chain covers two very different products moving through two very different systems. Collected plasma is frozen hard, at -25°C or colder, and held that way from the collection center through storage and often through an ocean or air crossing to a fractionation plant. Once that plant splits the plasma into its component proteins, the derivatives it produces, chiefly albumin and immunoglobulin, mostly leave the deep freeze behind and move as refrigerated or even room-temperature products instead. One raw material, two cold chains.
It sits in the knowledge base next to the other blood and biologic cold chain topics, because plasma sits at the frozen end of a spectrum that runs from ordinary refrigerated biologics through to the deep-frozen and cryogenic extremes.
Frozen collection and the -25°C floor
Whole blood donations are separated into plasma at the collection center and blood bank, then frozen fast enough and cold enough, typically -25°C or colder, to lock in the clotting factors that degrade first at warmer temperatures. That floor is colder than most frozen food or frozen pharma lanes run, closer to the range covered by dry ice than to an ordinary freezer truck, and it has to hold from the moment of freezing until the plasma is either transfused as fresh frozen plasma or handed to a fractionator. A single thaw-and-refreeze cycle is treated as a failure, not a recoverable event, the same way it would be for any other frozen biologic.
Fractionation plants and the split into derivatives
Fractionation is a large, capital-heavy industrial process that only a small number of plants worldwide run at scale, which means plasma routinely travels a long way, often across a border or an ocean, between where it is collected and where it is processed. That single step is the busiest part of the whole chain: bulk frozen plasma arrives in volume, and what leaves is a set of purified proteins, each with its own stability profile and its own storage rules downstream.
Albumin and immunoglobulin do not behave like the plasma they came from
Albumin is comparatively stable, and in some formulations does not need refrigeration at all, holding at room temperature for extended periods, which makes it one of the easier plasma derivatives to distribute. Immunoglobulin sits further up the sensitivity scale: most formulations need refrigeration and some need to stay frozen, and it commands a cold chain closer to a conventional refrigerated biologic drug than to the deep-frozen raw plasma it was purified from. Neither product carries the -25°C requirement of the plasma feeding the plant, because splitting out the target protein and stabilizing it in its final formulation is largely the point of the fractionation step.
Long frozen life against a short thawed one
Frozen plasma holds for a long time, commonly a year or more, which is what makes stockpiling it and shipping it internationally practical in the first place. Thawed plasma is a different story: once warmed for use, clotting factors start degrading on a clock measured in hours, not months, so a blood bank thaws only what a transfusion actually needs and treats a thawed unit as a short-dated product from that point on. That gap between the frozen shelf life and the thawed one is the reason plasma is frozen at every stage it can be and only thawed at the last possible point in the chain.
Bulk intercontinental lanes, not last-mile delivery
Most plasma cold chain volume moves as bulk freight between a handful of collection networks and a handful of fractionation plants, on air cargo or refrigerated ocean lanes built for pallet-scale frozen shipments, inside insulated shippers or reefer containers rather than single-unit packaging. That is a different problem from delivering a dose to one clinic or one patient. Where it does not fit is single-unit, direct-to-clinic shipping: a hospital blood bank orders finished derivative products or receives fresh frozen plasma through established blood-supply logistics, not through a courier network built for one-off shipments, because the frozen bulk lane and the specialized handling it requires do not scale down efficiently to a single unit.
Traceability tied to the temperature record
Every unit of plasma carries a documented chain of custody from the donor to the point it is transfused or handed to a fractionator, and the temperature record travels with it as part of that chain rather than as a separate log kept apart from the paperwork. A blood bank or plasma center that cannot show an unbroken cold record for a unit typically discards it rather than assume it stayed in range, because a frozen biologic with a gap in its record carries the same risk as one known to have thawed. That traceability requirement is also why plasma moves in identified batches rather than as loose stock: a temperature failure discovered downstream has to trace back to a specific collection run, a specific freezer, and a specific transport leg, so the affected units can be pulled without discarding an entire shipment that stayed in range throughout.